Dyne Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DYN Nasdaq 2836 www.dyne-tx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dyne Therapeutics, Inc.

Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone - Jun 5th, 2026 9:55 am
A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment Milestone - Jun 4th, 2026 9:15 pm
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) - Jun 3rd, 2026 5:30 am
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge - May 30th, 2026 12:12 pm
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean - May 30th, 2026 10:48 am
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy - May 27th, 2026 8:20 am
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) - May 26th, 2026 5:30 am
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients - May 21st, 2026 9:31 am
A Look At Dyne Therapeutics (DYN) Valuation As Phase 3 FORZETTO Trial Marks Key Development Milestone - May 21st, 2026 3:10 am
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 20th, 2026 3:30 pm
Dyne Therapeutics Initiates Phase 3 Trial of Potential Duchenne Muscular Dystrophy Treatment - May 20th, 2026 6:33 am
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval - May 20th, 2026 5:46 am
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - May 19th, 2026 11:37 am
Dyne Therapeutics to Participate in Upcoming Investor Conferences - May 13th, 2026 5:30 am
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know - May 11th, 2026 10:00 am
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - May 11th, 2026 5:30 am
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting - Apr 27th, 2026 2:34 pm
Could Dyne Therapeutics’ (DYN) AMCP Spotlight Reveal How New FDA Leadership May Shape Its Pipeline? - Apr 15th, 2026 7:06 am
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - Apr 1st, 2026 5:30 am
Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4 - Mar 27th, 2026 10:16 am